3 Hazardous Reasons To Steer Clear Of AstraZeneca plc

Royston Wild looks at why AstraZeneca plc (LON: AZN) is an exceptionally risky stock selection.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

shire

Today I am looking at why I believe AstraZeneca (LSE: AZN) (NYSE: AZN.US) is on course to endure lasting earnings weakness.

Patent problems continue to pummel revenues

AstraZeneca has taken an age to satisfactorily address the problem of patent expiration across many of its critical products, a crushing millstone on group turnover. Indeed, the drugs giant announced earlier this month that the loss of exclusivity on previous earnings drivers — which includes the likes of Seroquel IR, Atacand, Nexium and Merrem — drove revenues 8% lower during 2013 to $25.7bn. This in turn pushed operating profit 54% lower to $3.7bn.

The prospect of further patent troubles has prompted AstraZeneca to warn that it expects “a low-to-mid single digit percentage decline in revenue at constant exchange rates for 2014,” a result which is likely to cause core earnings per share “to decline in the teens.”

Paltry pipeline unlikely to offer near-term respite

AstraZeneca continues to chuck vast amounts of capital into its R&D operations in order to rectify its ailing revenues, and spent $1.43bn on new product development last year, up 8.3% from 2012.

The company is also hoovering up pharma companies across the globe to offset shortfalls in its organic product development. AstraZeneca bought out Bristol-Myers Squibb’s stake in their diabetes-combating joint venture just this month, while other major purchases over the past year include respiratory specialists Pearl Therapeutics and lipids experts Omthera Pharmaceuticals.

Although such measures have helped to boost the pipeline — 11 products entered Phase III trialling last year versus just six in 2012 — the route from laboratory to store shelf is of course a bumpy one which can take many years to complete. Indeed, chief executive Pascal Soriot warned that revenues will only recover to last year’s levels by 2017 as the exclusivity saga rumbles on.

A relatively expensive valuation

Still, investors have been unperturbed by these concerns, and AstraZeneca’s share price has shot almost 15% higher since the middle of January. But in my opinion this leaves the firm at the mercy of a severe price correction, particularly considering the superior strength of its pharmaceutical rivals.

Indeed, AstraZeneca now deals on a P/E rating of 15.6 for 2014, an expensive choice when compared against GlaxoSmithKline which currently trades on a multiple of 15.1 and has a much more bubbly product pipeline and consequently superior earnings prospects.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Royston does not own shares in any of the companies mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home
Investing Articles

3 dividend shares I’ve bought for the next decade!

I think these UK dividend shares can amplify my long-term passive income, and could even be on track to becoming…

Read more »

Investing Articles

If I’d put £5,000 in Scottish Mortgage shares at the start of 2024, here’s what I’d have now

Scottish Mortgage shares have staged a recovery lately, powered by the public and private growth stocks held in the portfolio.

Read more »

Happy couple showing relief at news
Investing Articles

9.9% dividend yield! Is this FTSE 100 stock a brilliant bargain?

This leading British enterprise looks like a delicious deal for passive income, trading at a low multiple while offering a…

Read more »

Investing Articles

If I’d put £5k in a FTSE 100 tracker fund 5 years ago, here’s what I’d have now

Investing in a FTSE 100 index fund is a terrific way to start building wealth passively with minimum effort. But…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

What’s going on with the Scottish Mortgage share price now?

The Scottish Mortgage share price is up 30% over the past 12 months, outperforming the index. Our writer explains why…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Here’s how investing £10 a day could create passive income of £27,573 a year!

Charlie Carman explains how he'd build a sizeable passive income portfolio over time by investing a tenner a day in…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

If I’d invested £10k in Greggs shares two years ago here’s what I’d have today

Harvey Jones wishes he'd bought Greggs shares two years ago and wonders whether the FTSE 250 stock still offers the…

Read more »

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

How I’d aim to turn an empty ISA into a £1m portfolio by targeting cheap shares

Harvey Jones is trawling the FTSE 100 for cheap shares to add to his Stocks and Shares ISA, in the…

Read more »